Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 10/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23798062 | 0.91 | CACNA1B (0.42) | CACNA1BBRD4HSD11B1MGLLBRD9 | |
| SCHEMBL25844092 | 0.91 | BRD4 (0.44) | CACNA1BBRD4HSD11B1MGLLBRD9 | |
| SCHEMBL23797638 | 0.90 | BRD4 (0.44) | CACNA1BBRD4MCHR1HSD11B1MGLL | |
| SCHEMBL25851626 | 0.89 | CYP3A4 (0.45) | CACNA1BBRD4MCHR1BRD9CYP3A4 | |
| SCHEMBL25091781 | 0.88 | CACNA1B (0.45) | CACNA1BBRD4MCHR1HSD11B1MGLL | |
| SCHEMBL25852375 | 0.87 | METAP2 (0.42) | CACNA1BBRD4MCHR1BRD9 | |
| SCHEMBL25091775 | 0.81 | BRD4 (0.41) | BRD4MCHR1BRD9BRD2BRD7 | |
| SCHEMBL25091776 | 0.81 | CACNA1B (0.44) | CACNA1BBRD4HSD11B1MGLLBRD9 | |
| SCHEMBL25091772 | 0.80 | BRD4 (0.46) | CACNA1BBRD4HSD11B1MGLLBRD9 | |
| SCHEMBL25844132 | 0.78 | BRD9 (0.45) | BRD4HSD11B1BRD9CYP3A4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CACNA1B 3822/4885BRD4 17/4885MCHR1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.